Inherited Orphan Blood Disorders Therapeutics Market to 2019 – Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Inherited Orphan Blood Diseases – Introduction 8
2.1 Overview 8
3 Inherited Orphan Blood Disorders – Therapeutic Landscape 9
3.1 Sickle Cell Anemia 9
3.1.1 Disease Overview 9
3.1.2 Revenues 14
3.1.3 Revenue Analysis by Country 14
3.1.4 Annual Cost of Therapy 18
3.1.5 Treatment Usage Patterns 19
3.1.6 Marketed Products 20
3.1.7 Market Drivers 21
3.1.8 Market Restraints 21
3.2 Sickle Cell Anemia: Research and Development Pipeline 22
3.2.1 Overview 22
3.2.2 Pipeline by Clinical Phase of Development 23
3.2.3 Trends in Sickle Cell Anemia Pipeline 28
3.2.4 Promising Pipeline Molecules 30
3.2.5 Key Takeaway 32
3.3 Thalassemia 33
3.3.1 Disease Overview 33
3.3.2 Revenues 38
3.3.3 Revenue Analysis by Country 39
3.3.4 Annual Cost of Therapy 43
3.3.5 Treatment Usage Patterns 44
3.3.6 Marketed Products 44
3.3.7 Market Drivers 46
3.3.8 Market Restraints 46
3.4 Thalassemia – Research and Development Pipeline 47
3.4.1 Overview 47
3.4.2 Pipeline by Clinical Phase of Development 48
3.4.3 Trends in Thalassemia Pipeline 51
3.4.4 Promising Pipeline Molecules 53
3.4.5 Key Takeaway 54
3.5 Hereditary Angioedema 55
3.5.1 Disease Overview 55
3.5.2 Revenues 56
3.5.3 Revenue Analysis by Country 57
3.5.4 Annual Cost of Therapy 61
3.5.5 Treatment Usage Patterns 62
3.5.6 Marketed Products 63
3.5.7 Market Drivers 64
3.5.8 Market Restraints 64
3.6 Hereditary Angioedema: Research and Development Pipeline 65
3.6.1 Overview 65
3.6.2 Pipeline by Clinical Phase of Development 66
3.6.3 Trends in Hereditary Angioedema Pipeline 69
3.6.4 Promising Pipeline Molecules 71
3.6.5 Key Takeaway 71
4 Inherited Orphan Blood Disorders Therapeutics – Strategic Consolidations 72
4.1 Segmentation by Year 72
4.2 Segmentation by Indication 72
4.3 Segmentation by Geography 73
4.4 Segmentation by Deal Value 73
4.5 Segmentation by Deal Type 74
4.6 Major Mergers and Acquisitions 74
4.7 Major Licensing Agreements 75
5 Inherited Orphan Blood Disorders Therapeutics – Appendix 76
5.1 Market Definitions 76
5.2 Abbreviations 76
5.3 Sources 76
5.4 Research Methodology 77
5.4.1 Coverage 77
5.4.2 Secondary Research 77
5.4.3 Primary Research 78
5.4.4 Therapeutic Landscape 78
5.4.5 Geographical Landscape 81
5.4.6 Pipeline Analysis 81
5.4.7 Competitive Landscape 81
5.4.8 Expert Panel Validation 81
5.5 Contact Us 81
5.6 Disclaimer 81